Molecular markers of early pancreatic cancer

Journal of Clinical Oncology

Volumn 23, Issue 20, 2005, Pages 4524-4531

  Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA2 PROTEIN; CA 19-9 ANTIGEN; FANCONI ANEMIA GROUP C PROTEIN; OSTEOPONTIN; PROTEIN KINASE LKB1; PROTEIN P16; TELOMERASE; TUMOR MARKER;

CANCER SCREENING; CANCER THERAPY; DNA METHYLATION; EARLY DIAGNOSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; GENETIC MARKER; ISOLATION AND PURIFICATION; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR;

CARCINOMA, PANCREATIC DUCTAL; GENETIC MARKERS; HUMANS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 22844448456     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.19.711     Document Type: Review

References (118)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. American Gastroenterological Association medical position statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117:1463-1484, 1999
3. Tascilar M, Skinner HG, Rosty C, et al: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7: 4115-4121, 2001
4. Yeo CJ, Cameron JL: Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg 383:129-133, 1998
5. Yeo CJ, Cameron JL, Lillemoe KD, et al: Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 221:721-731, 1995
6. Rosty C, Goggins M: Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 16:37-52, 2002
7. DiMagno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma: American Gastroenterological Association. Gastroenterology 117:1464-1484, 1999
8. Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85:350-355, 1990
9. Lamerz R: Role of tumour markers, cytogenetics. Ann Oncol 10:145-149, 1999 (suppl 4)
10. Tumour markers in gastrointestinal cancers-EGTM recommendations: European Group on Tumour Markers. Anticancer Res 19: 2811-2815, 1999
11. Rosty C, Goggins M: The early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 16:37-52, 2002
12. Brentnall TA, Bronner MP, Byrd DR, et al: Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131:247-255, 1999
13. Kim JE, Lee KT, Lee JK, et al: Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:182-186, 2004
14. Klein AP, Brune KA, Petersen GM, et al: Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64: 2634-2638, 2004
15. Tersmette AC, Petersen GM, Offerhaus GJ, et al: Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738-744, 2001
16. Murphy KM, Brune KA, Griffin C, et al: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 62:3789-3793, 2002
17. Goggins M, Canto M, Hruban R: Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 74:243-248, 2000
18. Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer: International Pancreatitis Study Group. N Engl J Med 328:1433-1437, 1993
19. Lowenfels AB, Maisonneuve P, DiMagno EP, et al: Hereditary pancreatitis and the risk of pancreatic cancer: International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89:442-446, 1997
20. Goggins M, Schutte M, Lu J, et al: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360-5364, 1996
21. Goldstein AM, Fraser MC, Struewing JP, et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970-974, 1995
22. Hruban RH, Petersen GM, Ha PK, et al: Genetics of pancreatic cancer: From genes to families. Surg Oncol Clin N Am 7:1-23, 1998
23. van der Heijden MS, Yeo CJ, Hruban RH, et al: Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585-2588, 2003
24. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221, 2003
25. Canto M, Goggins M, Yeo C, et al: Screening for pancreatic neoplasia in asymptomatic high risk individuals: A prospective. controlled study. AACR/Lustgarten Foundation Pancreatic Cancer Research Meeting, San Francisco, CA, June 25, 2004
26. Canto MI, Goggins M, Yeo CJ, et al: Screening for pancreatic neoplasia in high risk individuals. Clin Gastroenterol Hepatol 2:606-621, 2004
27. Brentnall TA, Bronner MP, Byrd DR, et al: Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131:247-255, 1999
28. Charpentier KP, Brentnall TA, Bronner MP, et al: A new indication for pancreas transplantation: High grade pancreatic dysplasia. Clin Transplant 18:105-107, 2004
29. Hruban RH, Takaori K, Klimstra DS, et al: An Illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28:977-987, 2004
30. Tollefson MK, Libsch KD, Sarr MG, et al: Intraductal papillary mucinous neoplasm: Did it exist prior to 1980? Pancreas 26:e55-e58, 2003
31. Sohn TA, Yeo CJ, Cameron JL, et al: Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 234:313-322, 2001
32. McCarthy DM, Maitra A, Argani P, et al: Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 11:238-243, 2003
33. Khalid A, Pal R, Sasatomi E, et al: Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut 53: 1860-1865, 2004
34. Yamada T, Nakamori S, Ohzato H, et al: Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: Correlation with clinicopathological features. Clin Cancer Res 4:1527-1532, 1998
35. Mulcahy HE, Lyautey J, Lederrey C, et al: A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 4:271-275, 1998
36. Wilentz RE, Chung CH, Sturm PD, et al: K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 82:96-103, 1998
37. Caldas C, Hahn SA, Hruban RH, et al: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 54: 3568-3573, 1994
38. Ohuchida K, Mizumoto K, Ishikawa N, et al: A highly sensitive and quantitative telomerase activity assay with pancreatic juice is useful for diagnosis of pancreatic carcinoma without problems due to polymerase chain reaction inhibitors: Analysis of 100 samples of pancreatic juice from consecutive patients. Cancer 101:2309-2317, 2004
39. Sullivan Pepe M, Etzioni R, Feng Z, et al: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054-1061, 2001
40. Koprowski H, Steplewski Z, Mitchell K, et al: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5: 957-971, 1979
41. Cao D, Hustinx SR, Sui G, et al: Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. Cancer Biol Ther 3:1081-1089, 2005
42. Hustinx SR, Cao D, Maitra A, et al: Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Ther 3:1254-1261, 2004
43. Fukushima N, Sato N, Prasad N, et al: Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene 23:9042-9051, 2004
44. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162:1151-1162, 2003
45. Sato N, Fukushima N, Maitra A, et al: Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 164:903-914, 2004
46. Sato N, Maehara N, Goggins M: Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 64:6950-6956, 2004
47. Zhou W, Sokoll LJ, Bruzek DJ, et al: Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 7:109-112, 1998
48. Ryu B, Jones J, Hollingsworth MA, et al: Invasion-specific genes in malignancy serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 61:1833-1838, 2001
49. Fukushima N, Koopmann J, Sato N, et al: Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol 2005, in press
50. Logsdon CD, Simeone DM, Binkley C, et al: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63:2649-2657, 2003
51. Han H, Bearss DJ, Browne LW, et al: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62:2890-2896, 2002
52. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al: Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21: 4587-4594, 2002
53. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al: Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63:8614-8622, 2003
54. Nakamura T, Furukawa Y, Nakagawa H, et al: Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23:2385-2400, 2004
55. Thomas AM, Santarsiero LM, Lutz ER, et al: Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200:297-306, 2004
56. Nowak NJ, Gailea D, Conroya JM, et al: Genome wide aberrations in pancreatic ductal adenocarcinoma. Cancer Gene Cyto2005, in press
57. Holzmann K, Kohlhammer H, Schwaenen C, et al: Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res 64:4428-4433, 2004
58. Aguirre AJ, Brennan C, Bailey G, et al: High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A 101:9067-9072, 2004
59. Sato N, Maitra A, Fukushima N, et al: Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 63:4158-4166, 2003
60. Sato N, Maehara N, Su GH, et al: Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95:327-330, 2003
61. Koopmann J, White CN, Zhang Z, et al: Serum markers in patients with resectable pancreatic adenocarcinoma: MIC-1 vs. CA19-9. Gastroenterology Digestive Diseases Week, Chicago, IL, May 14-19, 2005
62. Koopmann J, Buckhaults P, Brown DA, et al: Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10:2386-2392, 2004
63. Koopmann J, Fedarko NS, Jain A, et al: Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13:487-491, 2004
64. Bootcov MR, Bauskin AR, Valenzuela SM, et al: MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94: 11514-11519, 1997
65. Yokoyama-Kobayashi M, Saeki M, Sekine S, et al: Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. J Biochem (Tokyo) 122:622-626, 1997
66. Paralkar VM, Vail AL, Grasser WA, et al: Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 273: 13760-13767, 1998
67. Strelau J, Bottner M, Lingor P, et al: GDF-15/MIC-1 a novel member of the TGF-beta superfamily. J Neural Transm Suppl 60:273-276, 2000 (suppl)
68. Hromas R, Hufford M, Sutton J, et al: PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1354:40-44, 1997
69. Buckhaults P, Rago C, St Croix B, et al: Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 61:6996-7001, 2001
70. Welsh JB, Sapinoso LM, Su AI, et al: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61:5974-5978, 2001
71. Lee DH, Yang Y, Lee SJ, et al: Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648-4655, 2003
72. Baek SJ, Kim KS, Nixon JB, et al: Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59:901-908, 2001
73. Brown DA, Ward RL, Buckhaults P, et al: MIC-1 serum level and genotype: Associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 9:2642-2650, 2003
74. Chen R, Pan S, Brentnall TA, et al: Proteomic profiling of pancreatic cancer for biomarker discovery.
75. Koopmann J, Zhang Z, White N, et al: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860-868, 2004
76. Bhattacharyya S, Siegel ER, Petersen GM, et al: Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 6:674-686, 2004
77. Ransohoff DF: Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 97:315-319, 2005
78. Liotta LA, Lowenthal M, Mehta A, et al: Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst 97:310-314, 2005
79. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20:777-785, 2004
80. Baggerly KA, Morris JS, Edmonson SR, et al: Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97:307-309, 2005
81. Zhang Z, Bast RC, Jr., Yu Y, et al: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882-5890, 2004
82. Semmes OJ, Feng Z, Adam BL, et al: Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 51:102-112, 2005
83. Koomen JM, Shih LN, Coombes KR, et al: Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11:1110-1118, 2005
84. Shen J, Person MD, Zhu J, et al: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64:9018-9026, 2004
85. Shekouh AR, Thompson CC, Prime W, et al: Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 3:1988-2001, 2003
86. Gronborg M, Bunkenborg J, Kristiansen TZ, et al: Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3:1042-1055, 2004
87. Rosty C, Christa L, Kuzdzal S, et al: Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62:1868-1875, 2002
88. Berger DH, Chang H, Wood M, et al: Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer 85:326-332, 1999
89. Caldas C, Hahn SA, da Costa LT, et al: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32, 1994
90. Kalthoff H, Schmiegel W, Roeder C, et al: p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298, 1993
91. Moskaluk CA, Hruban RH, Kern SE: p16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140-2143, 1997
92. Tada M, Omata M, Kawai S, et al: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 53:2472-2474, 1993
93. Shi C, Eshleman SH, Jones D, et al: LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 1:141-147, 2004
94. Redston MS, Caldas C, Seymour AB, et al: p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54:3025-3033, 1994
95. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
96. Dong SM, Traverso G, Johnson C, et al: Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 93:858-865, 2001
97. Ahrendt SA, Hu Y, Buta M, et al: p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst 95:961-970, 2003
98. Sturm PD, Hruban RH, Ramsoekh TB, et al: The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 186:247-253, 1998
99. Ueki T, Toyota M, Sohn T, et al: Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60:1835-1839, 2000
100. Sato N, Rosty C, Jansen M, et al: STK11/ LKB1 Peutz-Jeghers Gene Inactivation in Intraductal Papillary-Mucinous Neoplasms of the Pancreas. Am J Pathol 159:2017-2022, 2001
101. Fukushima N, Sato N, Ueki T, et al: Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 160:1573-1581, 2002
102. Sato N, Ueki T, Fukushima N, et al: Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 123:365-372, 2002
103. Fukushima N, Walter KM, Uek T, et al: Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2:78-83, 2003
104. Ueki T, Walter K, Skinner H, et al: Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene 21:2114-2117, 2002
105. Matsubayashi H, Sato N, Fukushima N, et al: Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 9:1446-1452, 2003
106. Fukushima N, Sato N, Sahin F, et al: Aberrant methylation of suppressor of cytokine signalling (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 89:338-343, 2003
107. Sato N, Fukushima N, Maehara N, et al: SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22:5021-5030, 2003
108. Jansen M, Fukushima N, Rosty C, et al: Abberant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. Cancer Biol Ther 1:293-296, 2002
109. Sato N, Fukushima N, Maitra A, et al: Discovery of nobel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 1:3735-3742, 2003
110. Sato N, Fukushima N, Maitra A, et al: Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63:3735-3742, 2003
111. Fukushima N, Walter KM, Uek T, et al: Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2:78-83, 2003
112. Sato N, Parker AR, Fukushima N, et al: Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24:850-858, 2005
113. Polyak K, Li Y, Zhu H, et al: Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 20:291-293, 1998
114. Jones JB, Song JJ, Hempen PM, et al: Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res 61:1299-1304, 2001
115. Maitra A, Cohen Y, Gillespie SE, et al: The Human MitoChip: A high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res 14:812-819, 2004
116. Fliss MS, Usadel H, Caballero OL, et al: Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287:2017-2019, 2000
117. Sanchez-Cespedes M, Parrella P, Nomoto S, et al: Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res 61:7015-7019, 2001
118. Nomoto S, Yamashita K, Koshikawa K, et al: Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res 8:481-487, 2002